The Effect of QVAR on Lung Functioning in Chronic Obstructive Pulmonary Disease
Not Applicable
Terminated
- Conditions
- COPD
- Registration Number
- NCT00238082
- Lead Sponsor
- National Jewish Health
- Brief Summary
This is an investigator-sponsored research study to evaluate if treatment with HFA-134a beclomethasone (QVAR) has an effect on peripheral (or outer) airway inflammation and airway "remodeling" or scarring in subjects with COPD. Approximately 20 subjects with COPD will participate for approximately 7 weeks, with 10 receiving an active (BDP) inhaler with HFA-134a and 10 receiving a placebo.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
- COPD diagnosis
- FEV1/FVC<70%
- FEV1 50-80% predicted
- Albuterol response of <12% and <200mL or methacholine PC20 > 8mg/mL
- RV > 120% predicted
- DLCO < 80%
- smokers and nonsmokers
- Lower age limit 45 years
Exclusion Criteria
- Asthma
- Other chronic airway or parenchymal lung disease
- Other comorbid illness (including but not limited to DM, MI or CAD-related intervention in 6 months, neurologic disease, syncope)
- Use of any steroid (oral, IV, nasal, pulmonary) within 12 weeks
- Use of theophylline, leukotriene modifiers within 12 weeks
- Use of long-acting beta-agonists (formoterol, salmeterol) or anticholinergic (tiotropium)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Lung volumes such as residual volume (RV), thoracic gas volume, total lung capacity (TLC) and the RV/TLC ratio Spirometric response (FEV1)
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
National Jewish Medical and Research Center
🇺🇸Denver, Colorado, United States